What does Progyny do and what are its main business segments?

What factors drove the changes in Progyny's revenue and profit?

What is the revenue and EPS growth rate for Progyny year over year?

What were the key takeaways from Progyny’s earnings call?

What is Progyny's gross profit margin?

What were the key takeaways from Progyny's earnings call?

What guidance did Progyny's management provide for the next earnings period?

What is the market's earnings forecast for Progyny next quarter?

- **Record 2025 Performance**: $1.29B revenue (+10%), $222M EBITDA (+13%), 100% client retention.
- **New Services Expansion**: 2.7M members access postpartum/menopause care; 30% clients upsold benefits.
- **Progyny Select Launch**: Targets 50M lives in fully insured plans, expected to contribute from 2027.
- **2026 Guidance**: $1.355B-$1.405B revenue (5.1%-9% growth), $224M-$239M EBITDA.
- **Cost Efficiency**: Stock-based comp to drop 35% YoY; 75% EBITDA-to-cash conversion rate.
- **Strong Cash Position**: $310M cash, no debt, $84M share buybacks in Q4.

**【CEO Summary Section】**
- Progyny achieved record 2025 performance with $1.29B revenue and $222M adjusted EBITDA, up 10% and 13% YoY, respectively.
- 100% client retention, including all largest employers, driven by superior clinical outcomes and cost management.
- Expanded services to 2.7M members for pregnancy/postpartum/menopause, with 30% of clients upselling benefits.
- Launched Progyny Select for smaller employers, targeting 50M lives in fully insured plans, expected to contribute from 2027.
- Diversified client base with no single client >single-digit revenue and industries <15% of lives.

**【CFO Financial Commentary】**
- Q4 2025 revenue $332M (7% YoY growth, 21% ex-former client), exceeding high end of guidance by $11M.
- Full-year adjusted EBITDA margin expanded 200bps to 17.2%, driven by scale and cost efficiencies.
- Operating cash flow $210M (17% YoY growth), with $310M cash on hand and no debt.
- 2026 guidance: $1.355B-$1.405B revenue (5.1%-9% growth), $224M-$239M EBITDA, $1.19-$1.22 EPS.
- Stock-based comp to drop 35% YoY, reducing expense to 6% of revenue (vs. 10%+ in 2025).
- Q1 2026 revenue $319M-$332M (YoY -1.6% to +2.5%), reflecting typical Q1 cadence.

**【Q&A Key Highlights】**
- Membership count reduction (400K) due to administrative updates, not client attrition; guidance based on actual utilization, not population counts.
- Progyny Rx model maintains economics via rebates at point of sale, no pushback from employers.
- Progyny Select priced off smaller client experience, with guardrails like lifetime max claims and no individual opt-outs.
- New maternal health services growing but not yet material; will disclose when significant.
- 2026 pipeline strong with early wins, though no mega-deals yet; typical mid-year launches expected.
- CapEx $18.4M in 2025, expects step-up in 2026 but not doubling; cash conversion rate ~75%.
- No material treatment mix shifts; focus remains on high-quality, cost-effective care.

Progyny, Inc. (PGNY) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q3 revenue exceeded expectations, up 9% YoY (23% excluding a large client exit), driven by 900,000 new covered lives.
- **Client Retention**: Near 100% renewal rate for 2026, with 30% of clients expanding benefits, adding 2.7 million members to new services.
- **Strategic Expansion**: Launched a supplemental plan for small/mid-market companies and Progyny Global, targeting $200 million in buybacks to return value to shareholders.
- **Financial Strength**: Generated $156 million in operating cash flow year-to-date, with no debt and a strong balance sheet.
- **Guidance Update**: Full year revenue guidance raised to $1.263–$1.278 billion, reflecting 17.8%–19.2% growth excluding the large client.

**【Management Opening Remarks】**
- James Hart welcomed participants and outlined the call structure, emphasizing the company's strong performance and updated guidance. He reminded investors of forward-looking statements and the availability of non-GAAP financial measures in the press release.

**【CEO Summary Section】**
- **Q3 2025 Results**: Exceeded high-end guidance with revenue and profitability, driven by a successful selling season. Added 80 new logos and 900,000 covered lives, despite macroeconomic challenges.
- **Client Retention**: Near 100% renewal rate for 2026, with 30% of clients expanding benefits (e.g., adding Rx or donor tissue coverage).
- **New Services**: 2.7 million members will access expanded services (pregnancy, postpartum, menopause) in 2026, up 1.2 million from 2025.
- **Strategic Initiatives**: Launched a first-of-its-kind supplemental plan for small/mid-market companies and Progyny Global for multinational employers.
- **Share Repurchase Program**: Announced $200 million buyback program to return value to shareholders.

**【CFO Financial Commentary】**
- **Q3 Financials**: 
  - Revenue: $298.5 million (9% YoY growth, 23% excluding a large client exit).
  - Gross Margin: 23%.
  - Adjusted EBITDA: $45.3 million (17.5% margin).
  - Operating Cash Flow: $50 million (Q3) and $156 million (9M).
- **Full Year Guidance Update**: 
  - Revenue: $1.263–$1.278 billion (8.2%–9.5% YoY growth, 17.8%–19.2% excluding the large client).
  - Adjusted EBITDA: $216–$220 million.
- **Utilization Assumptions**: Narrowed to 1.05%–1.06% for 2025, reflecting cautious outlook on ART cycles.

**【Q&A Highlights】**
- **Selling Season Performance**: Despite initial pipeline delays, achieved 900,000 new lives, slightly below the 1 million target but still strong. Mix of high-value clients maintained guidance integrity.
- **Drug Pricing Impact**: Announced discounts on cash-pay medications unlikely to affect covered benefits; clients prioritize comprehensive coverage over cash discounts.
- **Layoff Impact**: No material impact on utilization from recent layoffs; clients focus on member experience and cost control.
- **New Products**: Expanded services (pregnancy, menopause) and Progyny Global will drive future growth, with minimal near-term expense impact.
- **Utilization Outlook**: Seasonal Q4 decline expected, but no long-term weakness; ART cycles per utilizer trends stable.


Progyny, Inc. (PGNY) Q3 2025 Earnings Call Transcript

- **Q2 Growth Milestones**: $332.9M revenue (+9.5% YoY), $58M adjusted EBITDA, and 23.7% gross margin. Full-year guidance raised to $1.235B-$1.270B.
- **Selling Season Strength**: 550+ clients, 6.8M lives, and wins across industries (tech, healthcare, manufacturing). Early pipeline comparable to last year, with 18% core growth.
- **Strategic Expansion**: Integrated leave navigation, global product suite, and partnerships with OURA and Amazon. Added pelvic floor therapy providers to address postpartum care.
- **Financial Discipline**: $55.5M Q2 cash flow, undrawn $200M revolver, and DSO improvement. Full-year ART cycles per utilizer 0.91-0.92, utilization 1.04%-1.06%.
- **Market Resilience**: No impact from layoffs on utilization; clients expand benefits despite macro uncertainty. Pharmacy growth to align with medical benefits by year-end.

**【CEO Summary Section】**
- **Record Q2 Results**: Revenue of $332.9M (+9.5% YoY), adjusted EBITDA of $58M (+6% YoY), and gross margin expansion to 23.7% (vs. 22.5% YoY). Full-year guidance raised to $1.235B-$1.270B in revenue.
- **Selling Season Progress**: Pipeline comparable to last year, with early wins spanning diverse industries (tech, healthcare, manufacturing) and sizes (1,000-100,000+ lives). New client additions offset slower start, with 550+ clients and ~6.8M covered lives post-Q2.
- **Strategic Initiatives**: Integration of BenefitBump for leave navigation, global expansion via Apryl, and partnerships with OURA (smart health tracking) and Amazon (benefits platform). Added pelvic floor therapy providers (Hinge Health, Origin) to address postpartum and menopause care.
- **Client Retention**: High renewal rates, with many expanding benefits (e.g., ART cycles per utilizer at 0.52, near historical highs).

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Fertility benefits ($214M, +11% YoY), pharmacy ($119M, +8% YoY). Excluding a large client transition ($17.2M Q2 contribution), core growth was 18% YoY.
- **Margins & Expenses**: Gross profit up 16% YoY to $79M. Sales & marketing (5.5% of rev) and G&A (10.9% of rev) reflect investments in product expansion and acquisitions. Adjusted EBITDA margin 17.4% (vs. 17.8% YoY).
- **Cash Flow & Balance Sheet**: $55.5M Q2 operating cash flow, $105M H1 total. Undrawn $200M revolver added for flexibility. DSO improved 13.5 days YoY.
- **Guidance Update**: Q3 revenue $290M-$305M (+1%-6% YoY, +14%-20% ex-transition). Full-year ART cycles per utilizer 0.91-0.92, utilization 1.04%-1.06%.

**【Q&A Key Highlights】**
- **Pipeline & Wins**: Early commitments comparable YoY in count and revenue, but lives trailing due to industry mix (higher tech, lower retail). Demographics expected to normalize by year-end.
- **Progyny Rx Growth**: First-half pharmacy growth lagged fertility benefits due to timing of initial consults. Full-year growth expected to align with medical benefits.
- **Market Trends**: No impact from layoffs on utilization; clients engage at normal pace. Interest in new products (leave navigation, global services) spans all client sizes.
- **ART Cycle Mix**: No significant shift in transfer vs. freeze activity; mix stable vs. prior quarters.
- **Client Retention**: No notable churn from large tech companies; benefits remain core to employee value propositions.

Progyny, Inc. (PGNY) Q2 2025 Earnings Call Transcript

- **Revenue Growth Accelerates**: Q1 2025 revenue up 16.5% to $324M, ART cycles hit record 16,160 (+9% YoY).
- **Margin Expansion**: Gross margin improved to 23.4%, driven by cost efficiency and mix gains.
- **Guidance Upped**: Full year 2025 revenue raised to $1.185B-$1.235B, reflecting strong client pipeline.
- **Market Shift**: 51% of U.S. births now in women ≥30, fueling demand for fertility and maternal care services.
- **Investment Payoff**: $15M in platform investments expected to drive long-term growth in new service modules.


**【CEO Opening Remarks】**
- Q1 2025 revenue grew 16.5% YoY to $324 million, driven by client expansion and covered lives growth.
- ART cycles reached a record 16,160 (+9% YoY), reflecting strong member engagement.
- Gross margin expanded to 23.4% (vs. 22.4% Q1 2024), benefiting from cost control and mix improvements.
- Full year 2025 revenue guidance raised to $1.185B-$1.235B (+1.5%-5.8% YoY), excluding a large client transition impact.

**【CFO Financial Highlights】**
- Fertility revenue up 22% to $206M; pharmacy revenue +9% to $118M, reflecting treatment mix shifts.
- Operating cash flow nearly doubled YoY to $50M, driven by profitability and working capital efficiency.
- Q2 2025 revenue expected $310M-$325M (+2%-7% YoY), with adjusted EBITDA of $49M-$53M.
- Full year adjusted EBITDA projected $190M-$203M, net income $42.4M-$51.8M.

**【Key Market Insights】**
- CDC data shows 51% of U.S. births now occur in women ≥30, driving demand for fertility and maternal care.
- 30% of existing clients expanded services in 2024, with new modules like menopause care gaining traction.
- Pipeline for 2026 selling season comparable to prior year, with focus on diversifying into 45+ industries.

**【Q&A Highlights】**
- Gross margin expansion in Q1 due to one-time mix benefits; full year 2025 margin growth tempered by $15M in platform investments.
- 2026 sales goal remains 1M+ new lives, with no signs of employer RFP delays despite macro uncertainty.
- Tariffs on pharmaceuticals not currently impacting costs, but flexibility exists to adjust client arrangements.
- Executive order on IVF access could enhance affordability, though policy details remain unclear.


Progyny (PGNY)-8 May 25-2025 Q1 Earnings call transcript

- **Q4 Strong Finish**: Revenue up 11% YoY to $298.4M, beating high-end guidance; 1.1M new lives added.
- **Service Expansion Success**: 40% of new clients adopt maternity/postpartum services; 20% of existing clients do so.
- **2025 Growth Path**: $1.175B-$1.225B revenue target; Amazon client transition contributes $37M-$40M in Q1-Q2.
- **Margin Stability**: Gross margin 21.3% (Q4), adjusted EBITDA up 10% YoY to $47.5M.
- **Digital Integration**: $15M+ investment in integrating acquisitions to enhance member experience.


**【CEO Opening Remarks】**
- Q4 2024 revenue and adjusted EBITDA exceeded high-end guidance, driven by 1.1 million new covered lives and 80 new clients.
- 40% of new clients adopted expanded services in maternity, postpartum, and menopause, reflecting strong market demand.
- Retained 99% of existing clients and added Cigna as first national health plan partner.
- 2025 investments focus on digital integration of recent acquisitions (e.g., BenefitBump) to enhance member experience and outcomes.

**【CFO Financial Highlights】**
- Q4 revenue: $298.4M (+11% YoY), full year: $1.17B (+7% YoY).
- Gross margin: 21.3% (Q4) / 21.7% (FY24), stable despite macro variability.
- Adjusted EBITDA: $47.5M (Q4, +10% YoY), FY24: $198.8M (+6% YoY).
- 2025 guidance: $1.175B-$1.225B revenue, $188M-$201M adjusted EBITDA.
- Amazon client transition: $37M-$40M Q1-Q2 revenue, negligible EBITDA contribution.

**【Q&A Key Takeaways】**
- **Amazon Impact**: 12% of 2024 revenue, replaced by new clients with lower utilization in first year.
- **New Services Growth**: 20% of existing clients adopt expanded services; 40% of new clients do so.
- **Competitive Strategy**: Focus on long-term value (cost control, outcomes) vs. short-term pricing competition.
- **International Expansion**: Recent acquisition enhances global fertility care offerings.
- **Utilization Volatility**: Short-term variability (e.g., Q3-Q4 2024) does not signal structural trend; long-term growth driven by client additions.


Actual			0.04	-0.02	0.05	0.07	0.15	0.19	0.17	0.15	0.05	0.09	0.13	0.03	0.18	0.15	0.16	0.13	0.17	0.17	0.11	0.12	0.17	0.19	0.15	0.14
Forecast			0.0241	-0.0242	0.0514	0.0644	0.0907	0.0834	0.0622	0.036	-0.0167	0.0125	0.03	0.02	0.0743	0.1028	0.1146	0.1075	0.1323	0.1694	0.143	0.096	0.1904	0.1582	0.1272	0.147
Surprise	0.00%	0.00%	+65.98%	+17.36%	-2.72%	+8.70%	+65.38%	+127.82%	+173.31%	+316.67%	+399.40%	+620.00%	+333.33%	+50.00%	+142.26%	+45.91%	+39.62%	+20.93%	+28.50%	+0.35%	-23.08%	+25.00%	-10.71%	+20.10%	+17.92%	-4.76%

PGNY

PGNY fundamentals

PGNY Q4 2025 Earnings

Earnings Call

You can ask Aime

PGNY

PGNY fundamentals

PGNY Q4 2025 Earnings

Earnings Call

PGNY Earnings Call Summary for Q4/20254:45 PM on Feb 26, 2026

PGNY Earnings Call Summary for Q3/20254:45 PM on Nov 6, 2025

PGNY Earnings Call Summary for Q2/20254:45 PM on Aug 7, 2025

PGNY Earnings Call Summary for Q1/20254:45 PM on May 8, 2025

PGNY Earnings Call Summary for Q4/20244:45 PM on Feb 27, 2025

You can ask Aime